Skip to content
Screener

Arcutis Biotherapeutics, Inc. ARQT Common stock, par value (in dollars per share)

Common stock, par value (in dollars per share) at other companies

Amgen logo
AmgenAMGN
$00.0%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$00.0%
Incyte logo
IncyteINCY
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
TTR
Turn Therapeutics Inc.TTRX
PTH
Pelthos TherapeuticsPTHS

Other financials

Income statement

See full
Revenue$129.9M+59.3%
Gross profit$118.9M+60.7%
Operating income$16.4M+212%
Net income$15.0M+194%
EPS (diluted)$0.11+185%

Balance sheet

See full
Cash & equivalents$34.4M-52.9%
Total debt$114.1M+3.6%
Total equity$220.6M+58.7%
Total assets$488.5M+38.6%

Cash flow

See full
Operating cash flow$12.6M
CapEx$158.0K+103%
Free cash flow$12.5M

Valuation

See full
Market cap$3.26B+91.5%
Enterprise value$3.34B+92.0%
P/S+0.6×

Profitability

See full
Gross margin91.1%+2.0pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp
FCF margin-52.5%-21.9pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.5×-0.3×
Current ratio2.9×-0.3×

Where this comes from

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The source filing: Arcutis Biotherapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:21 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001787306-26-000051
Line itemJune 30, 2026December 31, 2025
Total liabilities267,958243,494
Commitments and contingencies (Note 7)
Stockholders’ equity:
Common stock, $0.0001 par value; 300,000 shares authorized at June 30, 2026 and December 31, 2025; 125,591 and 123,333 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively1212
Additional paid-in capital1,355,5931,327,595
Accumulated other comprehensive income (loss)(656)(44)
Accumulated deficit(1,134,370)(1,138,084)
Total stockholders’ equity220,579189,479

Item 1. Financial Statements (Unaudited)

FAQ

What is Arcutis Biotherapeutics, Inc.'s common stock, par value (in dollars per share)?
Arcutis Biotherapeutics, Inc. (ARQT) reported common stock, par value (in dollars per share) of $0 in Q2 2026.
How has Arcutis Biotherapeutics, Inc.'s common stock, par value (in dollars per share) changed year-over-year?
Arcutis Biotherapeutics, Inc.'s common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0 to $0.
What is the long-term trend for Arcutis Biotherapeutics, Inc.'s common stock, par value (in dollars per share)?
Over 5 years (2020 to 2025), Arcutis Biotherapeutics, Inc.'s common stock, par value (in dollars per share) has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.
What does common stock, par value (in dollars per share) mean?
Common stock, par value (in dollars per share)

Ask your AI about Arcutis Biotherapeutics, Inc.'s common stock, par value (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude